Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New botox-like shot could ease stroke arm stiffness

NCT ID NCT06584240

Symptom relief Sponsor: JHM BioPharma (Tonghua) Co. , Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new type of botulinum toxin injection (JHM03) in 84 adults with arm muscle stiffness after a stroke. The injection is given into the affected muscles to relax them and improve movement. Researchers measured safety and how well it worked compared to a placebo over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
recombinant botulinum toxin type A (JHM03)
What this could lead to
If it works, this could offer a new treatment option to reduce arm muscle stiffness and improve daily function after stroke.
What could go wrong
This is an early-phase trial with only 84 participants, so results may not apply to everyone. The effects are temporary and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

84 people

The number who actually took part.

Started

Sep 2024

Finished

Jul 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent * Body weight ≥50Kg * Participants with stable post-stroke Spasticity (ULS) for at least 3 months * Participants with Modified Ashworth Scale (MAS) score of at least 2 at elbow flexor or wrist flexor or finger flexor * Participants with DAS score of at least 2 on the Principal Target of Treatment (PTT) (one of four functional domains: dressing, hygiene, limb position and pain) * Participants who have been stable for at least 1 month prior to study entry in terms of oral antispasticity Exclusion Criteria: * Previous use of any botulinum toxin within 6 months prior to screening, or plan to use any botulinum toxin during the study. * History of alcohol or drug abuse. * Known allergy or hypersensitivity to any component of the study products. * History of epilepsy * Known or suspected to be HIV positive, serologically positive for syphilis, or active hepatitis B or C * Any medical condition that may put the participant at increased risk for botulinum toxin type A use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Upper limb spasticity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Upper limb spasticity

Contacts and locations

Locations

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • Huai 'an Second People's Hospital

    Huai'an, Jiangsu, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Huazhong University of Science and Technology Union Hospital

    Shenzhen, Guangdong, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Rizhao People's Hospital

    Rizhao, Shandong, China

  • Shengjing Hospital affiliated to China Medical University

    Shenyang, Liaoning, China

  • The Fifth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The Second Hospital of Hebei Medical Hospital

    Shijiazhuang, Hebei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Yangzhi Affiliated Rehabilitation Hospital of Tongji University

    Shanghai, Shanghai Municipality, China

  • Yantai Mountain Hospital

    Yantai, Shandong, China

  • Zhujiang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.